Schizophrenia Research
Volume 71, Issue 1 , Pages 83-95 , 1 November 2004

The heterogeneity of schizophrenia in disease states

  • Penny E. Mohr

      Affiliations

    • Corresponding Author InformationCorresponding author. Centers for Medicare and Medicaid Services, ORDI/REG/DBR, Mail stop C3-19-07 7500, Security Boulevard, Baltimore, MD 21244, USA. Tel.: +1-301-656-7401; fax: +1-301-654-0629.
    • Centers for Medicare and Medicaid Services, ORDI/REG/DBR, Mail stop C3-19-07 7500, Security Boulevard, Baltimore, MD 21244, USA
    • ,
  • C.Michael Cheng

      Affiliations

    • PacifiCare, Medical Informatics, 5757 Plaza Drive, Mail Stop CY44-176 Cypress, CA 40630, USA
    • ,
  • Karl Claxton

      Affiliations

    • University of York, Department of Economics, Heslington, York, UK
    • ,
  • Robert R. Conley

      Affiliations

    • Maryland Psychiatric Research Center, Baltimore, MD, USA
    • ,
  • Jacob J. Feldman

      Affiliations

    • Senior Fellow NORC, 7500 Old Georgetown Road, Suite 620, Bethesda, MD, 20814, USA
    • ,
  • William A. Hargreaves

      Affiliations

    • UC-SF, School of Medicine, Department of Psychiatry, San Francisco, CA, USA
    • ,
  • Anthony F. Lehman

      Affiliations

    • U-MD, School of Medicine, Department of Psychiatry, Baltimore, MD, USA
    • ,
  • Leslie A. Lenert

      Affiliations

    • UC-SD, School of Medicine, Health Services Research and Development, San Diego, CA, USA
    • ,
  • Ramy Mahmoud

      Affiliations

    • Janssen Pharmaceutica Products, L.P., Medical Development, Titusville, NJ, USA
    • ,
  • Stephen R. Marder

      Affiliations

    • Mental Illness Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
    • ,
  • Peter J. Neumann

      Affiliations

    • Harvard School of Public Health, Boston, MA, USA

Received 29 May 2003 ,Revised 7 November 2003 ,Accepted 12 November 2003.

References 

  1. American Psychiatric Association . Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry. 1997;154:1–63 (April Suppl)
  2. Bilder RM, Mukhergee S, Rieder RO, Pandurangi AK. Symptomatic and neuropsychological components of defect state. Schizophrenia Bulletin. 1985;11:409–419
  3. Bond GR, McGrew JH, Fekete DM. Assertive outreach for frequent users of psychiatric hospitals: a meta-analysis. The Journal of Mental Health Administration. 1995;22(1):4–16
  4. Brown KW, White T. Syndromes of chronic schizophrenia and some clinical correlates. British Journal of Psychiatry. 1992;161:317–322
  5. Chouinard G, Albright P. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology. 1997;17(4):298–307
  6. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in “revolving door” schizophrenic patients. Journal of Clinical Psychiatry. 1996;57:337–345
  7. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Schizophrenia. 1993;16(2):295–3120
  8. Kaufman L, Rousseeuw PJ. Finding Groups in Data. An Introduction to Cluster Analysis. New York, NY: Wiley; 1990;
  9. Kay SR, Fishbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13(2):261–275
  10. Kitamura T, Suga R. Depressive and negative symptoms in major psychiatric disorders. Comprehensive Psychiatry. 1991;32:88–94
  11. Langley-Hawthorne C. Modeling the lifetime costs of treating schizophrenia in Australia. Clinical Therapeutics. 1997;19(6):1470–1495
  12. Lee TT, Zeigler JK, Sommi R, Sugar C, Mahmoud R, Lenert LA. Comparison of preferences for health outcomes in schizophrenia among stakeholder groups. Journal of Psychiatric Research. 2000;34(3):201–210
  13. Lenert LA, Ziegler J, Lee T, Sommi R, Mahmoud R. Differences in health values among patients, family members and providers for health outcomes in schizophrenia. Medical Care. 2000;38(10):1011–1021
  14. Lenert, L.A., Sturley, A.P., Rapaport, M.H., Chavez, S., Mohr, P.E., Rupnow, M. Public preferences for health states for schizophrenia and a mapping function to estimate utilities from Positive and Negative Symptom Scale scores. Schizophrenia Research, in press.
  15. Liddle PF. The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. British Journal of Psychiatry. 1987;151:145–151
  16. Lindenmayer J-P, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophrenia Research. 1995;14:229–234
  17. Mahmoud R. Protocol—A Randomized Trial to Assess the Outcomes and Costs of RISPERDAL Versus Conventional Antipsychotic Therapy in Patients with Chronic Schizophrenia. Titusville, NJ: Janssen Pharmaceutica; 1997;
  18. Marder SR, Davis JM, Chouinard G. The effects of risperidone on 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American Trials. Journal of Clinical Psychiatry. 1997;58:538–546
  19. Norman RMG, Malla AK. Correlations over time between dysphoric mood and symptomatology in schizophrenia. Comprehensive Psychiatry. 1994;35:34–38
  20. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports. 1962;10:799–812
  21. Peralta V, de Leon J, Cuesta MJ. Are there more than 2 syndromes in schizophrenia: a critique of the positive–negative dichotomy. British Journal of Psychiatry. 1992;161:335–343
  22. Peralta V, Cuesta MJ, de Leon J. An empirical analysis of latent structures underlying schizophrenic symptoms: a 4-syndrome model. Biological Psychiatry. 1994;36:726–736
  23. Phillips MR, Xiong W, Wang RW, Gao YH, Wang XQ, Zhang NP. Reliability and validity of the Chinese versions of the scale for the assessment of positive and negative symptoms. Acta Psychiatrica Scandinavica. 1991;84:364–370
  24. Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers, and psychiatrists. International Clinical Psychopharmacology. 1996;11:101–108
  25. Sax KW, Strakowski SM, Keck PE, Upadhyaya VH, West SA, McElroy SL. Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. British Journal of Psychiatry. 1996;168:68–71
  26. Schooler NR, Keith SJ, Severe JB, et al.  Relapse and rehospitalization rates during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Archives of General Psychiatry. 1997;54:453–463
  27. Strauss JS, Carpenter WT, Barko JJ. The diagnosis and understanding of schizophrenia: Part III. Speculations on the process that underlie schizophrenia symptoms and signs. Schizophrenia Bulletin. 1974;11:61–76
  28. Sugar CA, Sturm R, Lee TT, Sherbourne CD, Olshen RA, Wells KB, et al. Empirically defined health states for depression from the SF-12. Health Services Research. 1998;33(4):911–928
  29. Whiteford HA, Riney SJ, Csernansky JG. Distinguishing depressive and negative symptoms in chronic schizophrenia. Psychopathology. 1987;20:234–236

PII: S0920-9964(03)00383-9

doi: 10.1016/j.schres.2003.11.008

Schizophrenia Research
Volume 71, Issue 1 , Pages 83-95 , 1 November 2004

Article Tools

* Image Usage & Resolution